Rishabh Jain, Medical Oncologist at AIIMS, shared on X:
“My top 10 trials to watch at WCLC26.
WCLC is almost here.
These are the 10 lung cancer datasets I’m watching most closely.
- Small-cell lung cancer
- TAISHAN-302: Relapsed SCLC
- Can a new strategy finally beat topotecan
- ARTEMIS-008: Risvutatug rezetecan vs topotecan in relapsed SCLC
- ADCs challenge an old chemotherapy standard.
- DeLLphi-309: Tarlatamab extended-interval dosing
- Can DLL3 bispecific therapy become easier to deliver?
- IMDELLTRA + IMFINZI: Tarlatamab + durvalumab in 1L ES-SCLC
- A major frontline SCLC development.
- NSCLC EVOKE-03 / KEYNOTE-D46: Sacituzumab govitecan + pembrolizumab in PD-L1 ≥50% NSCLC
- Can an ADC improve on frontline IO?
- ADAURA 8-Year Update: Adjuvant osimertinib in EGFR-mutant NSCLC
- How durable is the survival benefit?
- PAPILLON OS: Amivantamab + chemotherapy in EGFR exon 20 insertion NSCLC
- The mature survival question.
- REZILIENT 3: Zipalertinib + chemotherapy in 1L EGFR exon 20 insertion NSCLC
- Another frontline challenge in exon 20 disease.
- DESTINY-Lung04: 1L trastuzumab deruxtecan in HER2-mutant NSCLC
- Could T-DXd move straight into frontline therapy?
- ARROS-1: Zidesamtinib in TKI-naïve ROS1 + NSCLC
- Next-generation ROS1 inhibition enters the spotlight.
Which WCLC26 dataset are you most excited about? ”
You can also read:
Sevabertinib Moves Into First-Line HER2-Mutant NSCLC With FDA Accelerated Approval
